(Q34218568)

31 July 2017

0 references

1 reference

title

Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

Jürgen De Fruyt

1

1 reference

31 July 2017

Ellen Deschepper

2

1 reference

31 July 2017

Kurt Audenaert

3

1 reference

31 July 2017

Eric Constant

4

1 reference

31 July 2017

Michel Floris

5

1 reference

31 July 2017

William Pitchot

6

1 reference

31 July 2017

Pascal Sienaert

7

1 reference

31 July 2017

Daniel Souery

8

1 reference

31 July 2017

Stephan Claes

9

1 reference

31 July 2017

language of work or name

English

0 references

publication date

22 September 2011

1 reference

Journal of Psychopharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

26

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

603-617

1 reference

Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

The armamentarium of treatments for bipolar disorder: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Bipolar (spectrum) disorder and mood stabilization: standing at the crossroads?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Antidepressants in bipolar disorder: the case for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Bipolar depression: a new role for atypical antipsychotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Approaches to heterogeneity in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Effectiveness of adjunctive antidepressant treatment for bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Clinical relevance of depressive symptom improvement in bipolar I depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

Effect of comorbid anxiety on treatment response in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111408461

21 January 2018

Identifiers

DOI

10.1177/0269881111408461

1 reference

31 July 2017

1 reference